C.M. Bidwell & Associates’s Beam Therapeutics BEAM Stock Holding History

C.M. Bidwell & Associates’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$357	Hold	15	–	–	﹤0.01%	468
2025 Q4	$416	Hold	15	–	–	﹤0.01%	473
2025 Q3	$364	Hold	15	–	–	﹤0.01%	479
2025 Q2	$255	Hold	15	–	–	﹤0.01%	439
2025 Q1	$293	Hold	15	–	–	﹤0.01%	428
2024 Q4	$372	Hold	15	–	–	﹤0.01%	469
2024 Q3	$367	Hold	15	–	–	﹤0.01%	487
2024 Q2	$351	Hold	15	–	–	﹤0.01%	462
2024 Q1	$496	Hold	15	–	–	﹤0.01%	445
2023 Q4	$408	Sell	15 -51	-77%	-$1.27K	﹤0.01%	459
2023 Q3	$1.59K	Hold	66	–	–	﹤0.01%	492
2023 Q2	$2.11K	Hold	66	–	–	﹤0.01%	468
2023 Q1	$2.02K	Hold	66	–	–	﹤0.01%	471
2022 Q4	$2.58K	Buy	66 +51	+340%	+$2.28K	﹤0.01%	418
2022 Q3	$1K	Hold	15	–	–	﹤0.01%	445
2022 Q2	$1K	Hold	15	–	–	﹤0.01%	450
2022 Q1	$1K	Buy	+15	New	+$984	﹤0.01%	487

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

C.M. Bidwell & Associates's BEAM Position: Q1 2026 in Review

C.M. Bidwell & Associates held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 15 shares worth $357. The position accounts for ﹤0.01% of the portfolio, ranked #468.

C.M. Bidwell & Associates first reported a position in BEAM in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.58K in Q4 2022. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

C.M. Bidwell & Associates held 15 shares of Beam Therapeutics worth $357 as of Q1 2026.
C.M. Bidwell & Associates left its Beam Therapeutics share count unchanged in Q1 2026.
Beam Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #468 holding.
C.M. Bidwell & Associates first reported a position in Beam Therapeutics in Q1 2022 and has held it in 17 quarters since.
C.M. Bidwell & Associates's Beam Therapeutics position peaked at $2.58K in Q4 2022.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.